SAN FRANCISCO, Oct. 5, 2023 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will provide third-party data on November 2 for the period ended September 30, 2023. Quarterly company update and reported financial results, 2023. The company will hold a conference call on November 2, 2023 at 4:30 pm Eastern Time.
Company updates and financial results will be provided via press release after the close and can be viewed in the press release on the investors section of Vir’s website at www.vir.bio. Participants can view the conference call via a webcast on the Events and Presentations page of Vir’s website at https://investors.vir.bio/events-presentations. A recorded version of the conference call will be posted on the website approximately two hours after the event and will be archived on the website for 30 days.
About Vir Biotechnology
Vir Biotechnology, Inc. is an immunology company focused on combining cutting-edge technologies to treat and prevent infectious diseases and other serious diseases. Vir has assembled two technology platforms designed to stimulate and enhance the immune system by leveraging key observations of natural immune processes. Its current clinical development pipeline includes product candidates targeting hepatitis B and D viruses, influenza A and B, human immunodeficiency virus and COVID-19. Vir is developing multiple preclinical drug candidates, including candidates targeting RSV/MPV and HPV. Vir frequently posts information on its website that may be important to investors.
Contact: Media Carly Scaduto Senior Director, Media Relations cscaduto@vir.bio +1 314-368-5189 Investors Sasha Damouni Ellis Executive Vice President, Chief Corporate Affairs Officer sdamouni@vir.bio